IDEXX Laboratories heads into mid-September with a notable split: options traders have turned their most bullish in over a year, while short sellers have quietly rebuilt positions over the past two weeks.
The clearest signal comes from options. The put/call ratio has dropped to 0.46, more than 1.25 standard deviations below its 20-day average of 0.59 — the lowest reading since the 52-week low of 0.44 set recently. That's a sharp reversal from late August, when the ratio was running near 0.69-0.73 on a consistent basis, reflecting meaningful downside hedging. The shift toward calls over the past two weeks suggests options traders are now positioned for recovery, even as the stock has fallen 7.3% over the past month to $510.73.
Short interest tells a less comfortable story. Bears have added meaningfully — SI climbed 13% on the week to 2.65% of the free float, with the bulk of the move occurring around September 9-10 when shares short jumped from roughly 1.87 million to over 2.1 million in a single session. That said, the absolute level remains modest. Borrow conditions reflect that: availability is vast, with roughly 3,871% of current short interest still available to borrow — more than enough headroom for any new shorts to enter without friction. Cost to borrow has edged higher, up 38% on the week to 0.55%, but that's still firmly in deep-value territory. The lending market is loose. The short positioning looks opportunistic rather than convicted.
The Street remains broadly constructive, though price targets have been drifting lower for months. Barclays maintained its Overweight rating in August but trimmed its target from $800 to $710, citing near-term pressure. Citi and UBS both nudged targets upward after Q2 results — UBS to $670, Citi to $670 — while holding Neutral stances. The mean target across the analyst community sits around $699, implying roughly 37% upside from current levels, though that gap has been closing. Bulls point to IDEXX's dominance in veterinary diagnostics, a sticky recurring revenue model through consumables and subscriptions, and the long-term tailwind from pet humanisation. Bears flag the valuation: P/E runs near 31.5x and EV/EBITDA near 22.7x, neither of which looks cheap when the forward earnings growth score ranks in the bottom quartile of the universe at just 26th percentile. The company beat estimates solidly in Q2 — ranking 70th percentile on EPS surprise — but analysts are asking how much of the good news is already priced in at these levels.
Among close peers, the week has been mixed. ISRG rallied nearly 8% on the week while RMD added 3.8% — both outpacing IDXX's 1.8% decline. STE and BAX fell 3.7% and 4.6% respectively, suggesting IDXX's relative performance sits in the middle of the peer pack rather than at either extreme. Institutional ownership is stable and concentrated: BlackRock holds 10.4% and State Street added 74,000 shares in the most recent reporting period. The ownership base is sticky and passive-heavy, which limits forced-selling risk but also caps the upside surprise from discretionary accumulation.
The only genuine insider activity worth noting is a director sale — Lawrence Kingsley sold 2,203 shares at $532 on September 4 for approximately $1.17 million, paired with an option exercise. The sale was not filed under a 10b5-1 plan, making it a discretionary transaction. One director exit near recent highs isn't a red flag on its own, but it adds a minor note of caution alongside the rebuilding short position. The next earnings date falls on November 6, giving the stock about seven weeks to find a floor before the market re-tests management's full-year guidance.
See the live data behind this article on ORTEX.
Open IDXX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
